Company intelligence / Profile preview

Innophore

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

Innophore develops AI-driven platforms to accelerate drug and enzyme discovery by analyzing protein structures and binding sites using advanced computational methods. Its Catalophore™ technology enables rapid identification of novel enzymes and drug candidates for both therapeutic and industrial applications. The company has contributed to large-scale drug repurposing efforts during COVID‑19 but does not have its own clinical pipeline or marketed products. It collaborates with major industry partners such as Merck and Henkel.

Therapeutic areas: OtherInfectious Diseases
Modalities: Protein (enzymes)Small molecule (drug discovery/repurposing focus)Biologic (biosimilars)
Industry: Drug Discovery Services

Partnerships

MerckHenkelNVIDIAAmazon Web ServicesGoogle Cloud

Beyond the preview

Go deeper on Innophore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innophore.

Explore the full profile